Physician profile
Karl W Haws
NPI 1194767897
$5,917.68
in general payments reported to CMS, 2019-2025
37 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $579 · 2021: $970 · 2022: $939 · 2023: $1,098 · 2024: $621 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,256 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,256.42 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $641.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $609.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $530.22 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $510.69 | 2021-2025 | |
| Pfizer INC. | $415.98 | 2019-2025 | |
| Astellas Pharma US INC | $386.66 | 2019-2024 | Veozah |
| Abbott Laboratories | $372.17 | 2020-2024 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $358.87 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $321.28 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $229.55 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $156.20 | 2019-2023 | |
| Amgen INC. | $146.58 | 2019-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $128.08 | 2019-2021 | |
| Horizon Therapeutics Plc | $118.48 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.97 | 2022-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Haws listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.